KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for NovoCure (NVCR) over the last 12 years, with Q3 2025 value amounting to $192.5 million.

  • NovoCure's Net Cash Flow rose 83147.71% to $192.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $155.1 million, marking a year-over-year increase of 37673.75%. This contributed to the annual value of -$76.3 million for FY2024, which is 16026.59% down from last year.
  • NovoCure's Net Cash Flow amounted to $192.5 million in Q3 2025, which was up 83147.71% from $22.4 million recorded in Q2 2025.
  • In the past 5 years, NovoCure's Net Cash Flow registered a high of $330.1 million during Q3 2021, and its lowest value of -$481.0 million during Q4 2021.
  • Moreover, its 5-year median value for Net Cash Flow was $20.7 million (2024), whereas its average is $5.2 million.
  • As far as peak fluctuations go, NovoCure's Net Cash Flow crashed by 459690.57% in 2021, and later soared by 243548.02% in 2024.
  • Quarter analysis of 5 years shows NovoCure's Net Cash Flow stood at -$481.0 million in 2021, then soared by 73.32% to -$128.4 million in 2022, then surged by 166.89% to $85.9 million in 2023, then crashed by 126.76% to -$23.0 million in 2024, then skyrocketed by 937.91% to $192.5 million in 2025.
  • Its Net Cash Flow was $192.5 million in Q3 2025, compared to $22.4 million in Q2 2025 and -$36.9 million in Q1 2025.